Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CK-301 (cosibelimab)
CK-301 · 1 trial · 13 indications
| Arm | Type | Description |
|---|---|---|
| CK-301 (cosibelimab) | EXPERIMENTAL | Part 1 - Dose Escalation; Part 2 - Dose Expansion |
| Name | Type | Description |
|---|---|---|
| CK-301 (cosibelimab) | DRUG | CK-301 will be administered in periods of 28-day cycles. |
Inclusion Criteria: * Signed written informed consent. * Male or female subjects aged greater than or equal to 18 years. * For NSCLC: Histologically or cytologically confirmed diagnosis of unresectable recurrent or metastatic non-small cell lung cancer. * For CRC: Histologically confirmed diagnosis...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
CK-301, also known as cosibelimab, is an investigational small molecule being studied for the treatment of advanced cancers, including lung neoplasms such as non-small-cell lung carcinoma and small cell carcinoma. It is also being evaluated in other solid tumors and hematologic malignancies, including head and neck cancer, melanoma, Merkel cell carcinoma, and classical Hodgkin lymphoma.
CK-301 targets PD-L1, a protein that helps cancer cells evade the immune system. By binding to PD-L1, CK-301 is designed to block the interaction between PD-L1 and its receptors, potentially restoring the immune system's ability to attack cancer cells. This mechanism is being investigated in a Phase 1 clinical trial.
CK-301 is being developed by Fortress Biotech, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol FBIO. The company is conducting clinical research on this investigational agent for the treatment of advanced cancers.
CK-301 is in Phase 1 clinical development. It is an investigational agent, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to evaluate its safety and efficacy in patients with advanced cancers.
CK-301 is being studied in a Phase 1 clinical trial with the identifier NCT03212404. This trial is titled "Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers" and is active but not recruiting participants. The trial has an enrollment of 272 participants and is being conducted in multiple countries.
Yes, CK-301 is also known as cosibelimab. Both names refer to the same investigational drug being developed by Fortress Biotech, Inc. for the treatment of advanced cancers, including lung neoplasms and other solid tumors.